PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy before surgery shows promise for esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Virus therapy joins chemo-radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial is testing whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The study involves 16 participants and focuses on side effects …
Matched conditions: PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: PATHOLOGIC STAGE IIIA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC